Dezima Pharma’s CETP Inhibitor, TA-8995, Phase 2b (TULIP)
Study Results Published in The Lancet
TA-8995 shows blockbuster potential with strong LDL-C reducing and unparalleled cholesterol efflux increasing properties

Naarden, The Netherlands, 03 June 2015 - Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, today announced the publication of the phase 2b TULIP study results with its CETP inhibitor, TA-8995, in the Lancet.

read more